As a chronic illness its costs to society are persistent.Schizophrenia is prevalent among a relatively small group of thepopulation, but not least owing to its serious nature, the diseaseplaces a disproportionately large economic burden upon society.
|
|
Пишет Юлий Давидов Жюльен Давидье Ta6y (![[info]](http://lj.rossia.org/img/userinfo.gif){kind=small} pharisee)@ 2007-01-07 14:04:00 |
 |
|
 |
|
|
|
|
|
|
 |
|
 |
сплетни фармакологии
<tr class="ProductTReven"><td>
Lu AA21004
Serotonin Modulator & Stimulator
Depression</td> <td></td> <td>
</td> <td class="BrownColor">2008+ </td> <td class="BrownColor"> </td> </tr> <tr class="ProductTReven"> <td colspan="5">
Common symptoms of depression are:
• Low mood
• Loss of pleasure or interest
• Loss of energy or increased tiredness </td> </tr> <tr class="ProductTReven"> <td align="right" width="240">
</td> <td colspan="4"></td> </tr> <tr> <td bgcolor="#02bb69" height="1"></td> <td></td> <td colspan="3" bgcolor="#02bb69"></td> </tr> <tr class="ProductTRodd"><td>Lu 31-130
Monoaminergic
Psychosis</td> <td></td> <td></td> <td class="BrownColor">2008+ </td> <td class="BrownColor"> </td> </tr> <tr class="ProductTRodd"> <td colspan="5"> </td> <td colspan="4"></td> </tr> <tr> <td bgcolor="#02bb69" height="1"></td> <td></td> <td colspan="3" bgcolor="#02bb69"></td> </tr> <tr class="ProductTReven"><td>Lu AA24530
Multiple target
Depression</td> <td></td> <td></td> <td class="BrownColor">2008+ </td> <td class="BrownColor"> </td> </tr> <tr class="ProductTReven"> <td colspan="5"> </td> </tr> <tr class="ProductTReven"> <td align="right" width="240"></td> <td colspan="4"></td> </tr> <tr> <td bgcolor="#02bb69" height="1"></td> <td></td> <td colspan="3" bgcolor="#02bb69"></td> </tr> <tr class="ProductTRodd"><td>Lu AA34893
Multiple target
Depression</td> <td></td> <td></td> <td class="BrownColor">2008+ </td> <td class="BrownColor"> </td> </tr> <tr class="ProductTRodd"> <td colspan="5"> </td> </tr> <tr class="ProductTRodd"> <td align="right" width="240"></td> <td colspan="4"></td> </tr> <tr> <td bgcolor="#02bb69" height="1"></td> <td></td> <td colspan="3" bgcolor="#02bb69"></td> </tr> <tr class="ProductTReven"><td>Lu AA44608
Selective NPY receptor antagonist
Mood disorders</td> <td></td> <td></td> <td class="BrownColor">2008+ </td> <td class="BrownColor"> </td> </tr> <tr class="ProductTReven"> <td colspan="5"> </td> </tr>
<tr class="ProductTReven"><td>
Serotonin Modulator & Stimulator
Depression</td> <td></td> <td>
Lu AA21004 belongs to a completely new chemical class of novel psychotropics, the bis-aryl-sulphanyl amines.
The pharmacology of this compound is markedly differentfrom any currently marketed antidepressants. The in vitropharmacological profile of the compound shows that the compoundcombines potent effect on several serotonin receptors and serotonintransporter proteins. The compound acts as a serotonin modulator andstimulator and modulates relevant parts of the neurochemicalarchitecture in the brain in a beneficial way.
Common symptoms of depression are:
• Low mood
• Loss of pleasure or interest
• Loss of energy or increased tiredness
Monoaminergic
Psychosis</td> <td></td> <td>
In clinicaldevelopment for the treatment of psychosis on the basis ofpharmacological data indicating antipsychotic activity combined with areduced side-effect liability in vivo. Lu 31-130 is an atypicalantipsychotic potentially capable of treating different psychoticsymptoms.
Schizophrenia is a severe, disabling and, most often, chronic braindisorder with a considerable impact on the patients' quality of life.Furthermore, schizophrenia affects the patients' family, servicesystems and society as a whole.
</td> </tr> <tr class="ProductTRodd"> <td align="right" width="240">
Multiple target
Depression</td> <td></td> <td>
LuAA24530 was selected as a development candidate based on its convincingeffect in preclinical animal models suggesting fast onset of action andincreased efficacy in the treatment of depression.
Depression is a disease that affects a large proportion of the population, and it is also one of the most disabling diseases.
Common symptoms of depression are:
• Low mood
• Loss of pleasure or interest
• Loss of energy or increased tiredness
Multiple target
Depression</td> <td></td> <td>
LuAA34893 was selected as a development candidate based on its convincingeffect in preclinical animal models suggesting a potential to improvethe treatment of depression and anxiety disorders.
Depression is a disease that affects a large proportion of the population, and it is also one of the most disabling diseases.
Common symptoms of depression are:
• Low mood
• Loss of pleasure or interest
• Loss of energy or increased tiredness
Selective NPY receptor antagonist
Mood disorders</td> <td></td> <td>
LuAA44608 is a selective NPY (Neuropeptide Y) receptor antagonist thatinteracts with one of the main systems in the brain mediating stressresponses. Preclinical studies suggest that this unique mechanismprevents and counteracts the vicious circle initiated by traumaticevents and long-term stress often resulting in major psychiatricdisorders.
Mood disorders are mentaldisorders whose essential feature is a disturbance of mood manifestedas one or more episodes of mania, hypomania, depression, or somecombination.
</td> </tr> <tr class="ProductTReven"> <td align="right" width="240">
